AtaiBeckley Inc.

Good morning and welcome to the Atai Life Sciences second quarter 2021 financial results and corporate update conference call. Currently, all participants are in a listen-only mode. This call is being broadcast live via the news and events section of the company's website at www.atai.life and is being recorded. For opening remarks, I would like to introduce Greg Weaver, Chief Financial Officer of Atai Life Sciences. Please go ahead.

Thank you and good morning. Welcome to our second quarter 2021 Attai Life Sciences financial results and corporate update conference call. The press release reporting our financial results is available in the investors and media section of our website at www.attai.life. And our quarterly report on Form 10-Q ended June 30, 2021, will file today with the SEC. Joining me today are Florian Brand, our co-founder and CEO, Dr. Srini Rao, our co-founder and chief scientific officer, and Christian Angemeyer, founder and chairman. During today's call, we'll be making certain forward-looking statements that are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. While these statements represent management's current expectations and projections about future results and performance as of today, the TIE's actual results are subject to many risks and uncertainties that could cause actual results to differ materially from those expectations. In addition to any risks highlighted during the call, these statements are subject to various risks that are described in our filings made with the Securities and Exchange Commission, including our final prospectus filed with the SEC on June 21 of 2021. Your caution not to place undue reliance on these forward-looking statements, which speak only as of today, August 16, 2021, and except as may be required by applicable law, a TIE disclaims any obligation to update such statements even if management's views change. I'd now like to turn the call over to Atai's CEO, Florian Brand. Florian?

Good morning, everyone. Thank you all for joining our first earnings call following our successful completed IPO in NASDAQ in June, where we raised $259 million. We are thrilled by the enthusiastic response to our mission from the investor community, and we intend to use these proceeds to continue advancing our decentralized drug development platform in two ways. First, to by executing on our existing pipeline, and second, by continuing to incubate, acquire, and invest in new programs and enabling technologies. With our unique approach, we aim to become the leading drug development company focused on mental health. We will do so by transforming and advancing the treatments of patients with the ultimate objective to heal mental health disorders so that everyone everywhere can live a more fulfilled life. And now it gives me great pleasure to introduce you to my visionary co-founder and our board chairman, Christian Anamayo. Christian.